

Receipt
IFW

DOCKET NO. 17629(AP)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bakhit et al.
Serial No.: 10/521,367
Filed: January 12, 2005
Customer No.: 51957
Conf. No.: 2266
Group Art Unit: 1711

For: COMPOSITIONS AND METHODS COMPRISING
PROSTAGLANDIN RELATED COMPOUNDS AND TREFOIL
FACTOR PEPTIDES FOR THE TREATMENT OF GLAUCOMA
WITH REDUCED HYPEREMIA
Examiner: Not Yet Assigned

I hereby certify that this correspondence is being
deposited with the United States Postal Service
as first class mail in an envelope addressed to:
Attn: Filing Receipt Corrections, Commissioner
for Patents and Trademarks, P.O. Box 1450,
Alexandria, VA 22313-1450 on:

7-1-05

(Date of Deposit)

BONNIE FERGUSON
Printed Name of Person Making Deposit

Bonnie Ferguson
Signature

7-1-05

Date of Signature

NOTICE OF CORRECTION OF FILING RECEIPT

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

Please correct the filing receipt as follows:

TITLE:

Delete "compound" and insert in place thereof --compounds--

Please charge deposit account 01-0885 if there is a fee required to make this correction.


Dated: 7-1-05

Respectfully submitted,

By:

Brent A. Johnson
Brent A. Johnson
Registration No. 51,851
Attorney of Record
ALLERGAN, INC.- T2-7H
Legal Department
2525 Dupont Drive
Irvine, CA. 92612

Telephone: (714) 246-4348
Facsimile: (714) 246-4249



Received

Page 1 of 2

MAY 23 2005

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/521,367	01/12/2005	1711	1400	17629(AP)		28	3

Allergan Inc
2525 Dupont Drive
Irvine, CA 92612

CONFIRMATION NO. 2266

FILING RECEIPT



OC000000016008333

Date Mailed: 05/17/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Peter G Bakhit, Huntington Beach, CA;
Richard Graham, Irvine, CA;
Orest Olejnik, Coto de Caza, CA;

Power of Attorney: None

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/US04/27777 08/25/2004

Foreign Applications

Projected Publication Date: 03/02/2006

Non-Publication Request: No


Early Publication Request: No

Title

Compositions and methods comprising prostaglandin related compound and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia

COMPOUNDS

CPI
Sh



DOCKET 17629 (AP)

COMPOSITIONS AND METHODS COMPRISING PROSTAGLANDIN-RELATED COMPOUNDS AND TREFOIL FACTOR FAMILY PEPTIDES FOR THE TREATMENT OF GLAUCOMA WITH REDUCED HYPEREMIA

5

Field of the Invention

The present invention relates to pharmaceutical compositions comprising prostaglandin-related compounds and trefoil factor family peptides.

10

Background of the Invention

Description of Related Art

15

Active drugs often have undesirable side effects at their therapeutically effective concentrations. This is particularly problematic for topical use in sensitive areas such as the eyes, where irritation is very difficult to avoid even for relatively mild drugs. As a result, formulating topical ophthalmic drugs is a particularly challenging problem. This is unfortunate because topical ophthalmic use of drugs has been found to be very useful in managing many conditions affecting the eye such as dry eye, infection, inflammation, allergy, and glaucoma. Glaucoma is a particularly devastating disease of the eye characterized by increased intraocular pressure, which is often treated by topical ophthalmic application of a drug. Glaucoma occurs in about 2% of all persons over the age of 40 and may be asymptotic for years before progressing to rapid loss of vision. In cases where surgery is not indicated, many drugs have been found to be useful in treating glaucoma by topical application including β -adrenoreceptor antagonists and α_2 -adrenoreceptor agonists. Recently, prostaglandins have been shown to be particularly useful in the topical treatment of glaucoma.

25
30

Whereas prostaglandins appear to be devoid of significant intraocular side effects, ocular surface (conjunctival) hyperemia, foreign-body sensation, and itching (pruritus) have been consistently associated with the topical ocular use of such compounds, in particular $\text{PGF}_2\alpha$ and its prodrugs, e.g., its 1-isopropyl-ester,